Recent News & Articles
NRx Pharmaceuticals, Inc. today announced its financial results for the third quarter of 2022 and provided a business and clinical update.
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx Pharmaceuticals”), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.
NRx Pharmaceuticals, Inc. today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.
NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).
NRx Pharmaceuticals, Inc. today announced that it has obtained approximately $11 million in unsecured debt financing (the “Note”) from Streeterville Capital, LLC, a Utah limited liability company.
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference
NRx Pharmaceuticals, Inc. today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company’s business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.
NRx Press Archives
Edward Woo, CFA
Senior Research Analyst, D.O.R.
Ascendiant Capital Markets LLC – Member FINRA & SIPC
H.C. Wainwright & Co., LLC
41st Annual J.P. Morgan Health Care Conference
January 9-12, 2023
Westin St. Francis Hotel
San Francisco, CA
Cantor Neurology & Psychiatry Conference
October 6-7, 2022
Ritz Carlton Hotel
San Francisco, CA
HC Wainwright 24th Annual Global Investment Conference
September 12-14, 2022
Lotte New York Palace Hotel
New York, NY